The $200 Billion Weight-Loss Drug Market Is Just Getting Started

In 2020, Novo Nordisk was a respected but unremarkable Danish pharmaceutical company with a market capitalisation of around $120 billion. Today, it is the most valuable company in Europe, worth more than $600 billion, and its Ozempic and Wegovy franchises have fundamentally changed the conversation about obesity, cardiovascular disease, and the limits of pharmacological intervention.

The GLP-1 revolution — named for the glucagon-like peptide-1 receptor agonists that underpin these drugs — is still in its early innings. Analysts at Goldman Sachs estimate that the global obesity drug market could reach $200 billion by 2030, up from approximately $24 billion today.

Beyond Weight Loss

The most exciting — and commercially significant — development in the GLP-1 space is the emerging evidence that these drugs do far more than suppress appetite. Clinical trials have shown meaningful reductions in cardiovascular events, improvements in kidney function, and potential benefits in addiction, sleep apnoea, and even cognitive decline.